Literature DB >> 12839982

P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0-G1 cell cycle arrest.

Pamela P McKenzie1, Mary K Danks, Richard W Kriwacki, Linda C Harris.   

Abstract

In normal cells in which DNA has been damaged, p53 induces the expression of p21(Waf1/Cip1); p21, in turn, binds to cyclin-dependent kinase 2 (cdk2) and inhibits its function. Inhibition of cdk2 results in cell cycle arrest in G(0)-G(1). Although p53 is transcriptionally active and induces p21 expression in neuroblastoma (NB) cells, the G(0)-G(1) checkpoint is attenuated. Here we report that the mechanism that mediates this defect in NB cells is the inability of p21 to bind to, or inhibit the activity of cdk2. However, when recombinant p21 protein was added to NB cell extracts in vitro, the protein inhibited the activity of cdk2. This finding suggests that endogenous p21 protein in NB cells is inactive and may be bound either to a protein complex or in a conformation that precludes its binding to cdk2. The dysfunction of p21 in NB cells represents a novel mechanism by which the G(0)-G(1) cell cycle checkpoint can be inactivated. This mechanism may be important in regulating the growth of NB and potentially other types of tumors. Cdk inhibitors currently being developed for clinical use may be useful therapy for tumors such as NB in which endogenous cdk inhibitors are defective.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839982

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas.

Authors:  Pritha Paul; Lauren A Gillory; JungHee Kang; Jingbo Qiao; Dai H Chung
Journal:  Surgery       Date:  2010-10-29       Impact factor: 3.982

2.  MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.

Authors:  S Donzelli; G Fontemaggi; F Fazi; S Di Agostino; F Padula; F Biagioni; P Muti; S Strano; G Blandino
Journal:  Cell Death Differ       Date:  2011-12-23       Impact factor: 15.828

3.  Antitumor activity of erythromycin on human neuroblastoma cell line (SH-SY5Y).

Authors:  Jia Yongsheng; Ma Xiaoyun; Wei Xiaoli; Li Xin; Yan Haitao; Liu Xiaoyan; Zheng Jianquan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-02-19

4.  Autocrine proliferation of neuroblastoma cells is partly mediated through neurokinin receptors: relevance to bone marrow metastasis.

Authors:  Indroneil Mukerji; Shakti H Ramkissoon; Kavitha K R Reddy; Pranela Rameshwar
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 5.  Cellular senescence in neuroblastoma.

Authors:  Sofia Zanotti; Bieke Decaesteker; Suzanne Vanhauwaert; Bram De Wilde; Winnok H De Vos; Frank Speleman
Journal:  Br J Cancer       Date:  2022-02-23       Impact factor: 9.075

6.  Inhibitory effects of NO-fluvastatin on proliferation of human lens epithelial cells in vitro by modulating cell cycle regulatory proteins.

Authors:  Zhi Wang; Ruiying Gao; Qianqian Shi; Yukan Huang; Wen Chen; Kaiying Shi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-10-10

7.  CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.

Authors:  Sina Gogolin; Volker Ehemann; Gabriele Becker; Lena M Brueckner; Daniel Dreidax; Steffen Bannert; Ingo Nolte; Larissa Savelyeva; Emma Bell; Frank Westermann
Journal:  Cell Cycle       Date:  2013-03-05       Impact factor: 4.534

8.  Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest.

Authors:  Annika Järviluoma; Emma S Child; Grzegorz Sarek; Papinya Sirimongkolkasem; Gordon Peters; Päivi M Ojala; David J Mann
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

9.  A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.

Authors:  Brittney-Shea Herbert; Rebecca A Chanoux; Yunlong Liu; Peter H Baenziger; Chirayu P Goswami; Jeanette N McClintick; Howard J Edenberg; Robert E Pennington; Steven M Lipkin; Levy Kopelovich
Journal:  Oncotarget       Date:  2010-10

10.  Development of a tumor-selective approach to treat metastatic cancer.

Authors:  Karen S Aboody; Rebecca A Bush; Elizabeth Garcia; Marianne Z Metz; Joseph Najbauer; Kristine A Justus; Doris A Phelps; Joanna S Remack; Karina Jin Yoon; Shanna Gillespie; Seung U Kim; Carlotta A Glackin; Philip M Potter; Mary K Danks
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.